bioRxivMolecular BiologyPreprint
SERF deletion modifies amyloid aggregation in a mouse model of Alzheimer's disease
Esther Stroo, Leen JansseniD, Olga SiniD, Wytse Hogewerf, Mirjam H. KosteriD, Liesbeth HarkemaiD, Sameh A. YoussefiD, Natalie BeschörneriD, Anouk H. G. WoltersiD, Björn BakkeriD, Lore BeckeriD, Lillian GarrettiD, Susan MarschalliD, Sabine M. HölteriD, Wolfgang WurstiD, Helmut FuchsiD, Valérie Gailus‐DurneriD, Martin Hrabě de AngelisiD, Amantha ThathiahiD, Floris FoijeriD, Bart van de SluisiD, Jan van Deursen, Mathias JuckeriD, Alain de BruiniD, Ellen A. A. NolleniD
Abstract
In age-related neurodegenerative disease, like Alzheimers and Parkinsons disease, disease-specific proteins become aggregation-prone and form amyloid-like deposits. Depletion of SERF proteins ameliorates this toxic process in worm- and human cell models for disease. Whether SERF modifies amyloid pathology in mammalian brain, however, has remained unknown. Here, we generated SERF2 brain-specific knockout mice which, unlike full body knockout mice, were viable, and showed no major behavioral and cognitive abnormalities. We combined these knockout mice with the APPPS1 mouse model for human amyloid beta aggregation. Using structure-specific amyloid dyes, previously used to distinguish amyloid polymorphisms in human brain, we show that knockout of SERF2 alters the structure of amyloid fibrils and deposits. Moreover, scanning transmission electron microscopy revealed thicker, shorter and more densely packed amyloid in absence of SERF2. Altogether, our data reveal pleiotropic functions of SERF in development and aging and support a function as a modifier of amyloid aggregation in mammalian brain. Our results indicate that single cellular factors like SERF can determine the structural outcome of amyloid aggregation, offering possibilities for polymorphism-based disease interventions.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Amyloid fibrils in Alzheimer's disease differently modulate sleep and cortical oscillations in mice depending on the type of amyloid
Tomomi Sanagi, Masaki Okumura, … Tomomi Tsunematsu·Biophysical ChemistryPeer-reviewed·Feb 25, 2026
- The cellular modifier MOAG-4/SERF drives amyloid formation through charge complementation
Anita Pras, Bert Houben, … Ellen A. A. Nollen·The EMBO JournalPeer-reviewed·Oct 7, 2021
- Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
Laura Sebastián Monasor, Stephan A. Müller, … Sabina Tahirović·eLifePeer-reviewed·Jun 8, 2020
- Ageing-associated myelin dysfunction drives amyloid deposition in mouse models of Alzheimer's disease
Constanze Depp, Ting Sun, … Klaus‐Armin Nave·NaturePeer-reviewed·May 31, 2023
- Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimers disease like pathology
Jeffrey N. Savas, Yizhi Wang, … John R. Yates·Cell ReportsPeer-reviewed·Nov 1, 2017
- Increased soluble amyloid-beta causes early aberrant brain network hypersynchronisation in a mature-onset mouse model of amyloidosis
Inès R. H. Ben-Nejma, A Keliris, … Georgios A. Keliris·Acta Neuropathologica CommunicationsPeer-reviewed·Nov 14, 2019